A groundbreaking fat-burning injection has emerged, offering potential weight loss benefits without reducing food intake. Studies on animals indicate that the new medication, RES-010, enhances the body’s ability to process food efficiently, preventing it from being stored as fat. Notably, mice treated with this weekly jab experienced weight loss while consuming the same amount of food as untreated mice.
Initial research presented at the European Association for the Study of Diabetes conference in Vienna revealed that the injection, which targets an RNA molecule called miR-22, serves as a key regulator in various obesity-related processes. These processes encompass fat breakdown and utilization, mitochondrial function, and adipose tissue functionality. Human trials are now underway to assess the safety and efficacy of the injection.
Dr. Riccardo Panella, CEO of Resalis Therapeutics, highlighted that RES-010 reprograms cellular fat metabolism and energy utilization, promoting mitochondrial activity and conversion of white fat to brown fat. This innovative approach aims to deliver sustainable weight loss and enhance metabolic health by optimizing liver function.
Despite the promising prospects, some experts urge caution and emphasize the need for additional evidence to validate the drug’s purported benefits. Detailed findings are awaited to comprehensively evaluate the metabolic effects of RES-010.
While appetite-suppressing injections like Mounjaro and Wegovy are recognized for their potential in combating obesity, their availability remains limited due to global shortages. The NHS prioritizes individuals with severe obesity for such treatments through specialized weight loss services, given the constraints on widespread provision.
Approximately 1.5 million Britons are estimated to receive weight loss injections, primarily through private prescriptions, underscoring the demand for alternative obesity management strategies. These injections modulate hunger hormones to slow digestion and reduce appetite, necessitating comprehensive lifestyle support for sustained results.
Studies indicate that users of GLP-1 injections may experience muscle loss alongside fat reduction. Without lifestyle modifications, regaining fat mass post-treatment cessation is common, while muscle retention remains a challenge.
This website and its partners use cookies and device identifiers to enhance user experience, analyze site usage, and deliver personalized advertising. Users can manage data sharing preferences by adjusting settings on the webpage. Continued use of the services implies consent to cookie usage and adherence to privacy and terms policies.